Table 3.

Efficacy of Pralsetinib in ARROW trial

	Overall (n = 116)	Prior platinum treatment (n = 80)	No prior systemic treatment (n = 26)	Measurable Brain Metastases (n = 9)
ORR, %	65 (5% CI 55–73)	61 (95% CI 50–72)	73 (95% CI 52–88)	55
DOR	NR	–	–	–
DCR, %	93 (87–97)	95 (95% CI 88–99)	88 (9% CI 70–98)	–

ORR, Objective Response Rates; DOR, Duration Of Response; DCR, Disease Control Rates. ORR was similar regardless of RET fusion partner, prior therapies, or central nervous system involvement. Overall, there were 7 (6%) completed responses, 4 (5%) in prior platinum patients and 3 (12%) in treatment naïve patients